Kurt Brunden, PhD

Kurt Brunden, PhDProfessor, Research Faculty

Scientific Director, Marian S. Ware Alzheimer and Benaroya Parkinson's Disease Drug Discovery Programs

Mailing Address:

University of Pennsylvania School of Medicine
3600 Spruce Street, 640B Maloney Building / 4283
Office: 215-615-5262
Lab: 215-662-3292
Fax: 215-349-5909

As Director of CNDR Drug Discovery, Dr. Brunden oversees a research team that is responsible for translating basic research discoveries made within CNDR into programs that will ultimately lead to new therapeutic treatments for neurodegenerative disease. This encompasses a variety of research activities, including further validation of putative drug targets, development of high-throughput assays to allow evaluation of small molecule compounds to such drug targets, in vitro and in vivo pharmacological characterization of active compounds identified during compound screening, and medicinal chemistry refinement of prototype lead compounds to improve drug efficacy, pharmacokinetics, and safety.

Select Publications

Brunden KR, Ballatore C, Lee VM-Y, Smith, AB III and Trojanowski (2012) Brain-penetrant microtubule stabilizing compounds as potential therapeutic agents for tauopathies. Biochem. Soc. Trans., 40:661-666

Cramer, PE, Cirrito JR, Wesson DW, Lee DCY, Karlo JC, Zinn AE, Casali BT, Restivo JL, Goebel WD, James MJ, Brunden KR, Wilson DA and Landreth GE (2012) ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in mouse models of Alzheimer’s disease. Science, 335:1503-1506.

Zhang B, Carroll J, Trojanowski JQ, Yao Y, Iba M, Potuzak JS, Hogan AL, Xie SX, Ballatore C, Smith AB III, Lee VMY and Brunden KR (2012) The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, cognitive deficits, neurotoxicity and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J. Neurosci., 32:3601-3611.

Ballatore C, Crowe A, Piscitelli F, James M, Lou K, Rossidivito G, Yao Y, Trojanowski JQ, Lee VM-Y, Brunden KR and Smith AB III (2012) Aminothienopyridazine inhibitors of tau aggregation: evaluation of structure-activity relationship leads to selection of candidates with desirable in vivo properties. Bioorg. Med. Chem. 20:4451-4461.

Soper JH, Sugiyama S, Herbst-Robinson K, James MJ, Wang X, Trojanowski JQ, Smith AB III, Lee VM-Y, Ballatore C and Brunden KR (2012) Brain-penetrant tetrahydronaphthalene thromboxan A2-prostanoid (TP) receptor antagonists as prototype therapeutics for Alzheimer’s disease. ACS Chem. Neurosci., in press.

Ballatore C, Soper JH, Piscitelli F, James M, Huang L, Atasoylu O, Huryn DM, Trojanowski JQ, Lee VM-Y, Brunden KR and Smith AB III (2011) Cyclopentane-1-3-dione: a novel isostere for the carboxylic acid functional group. Application to the design of potent thromboxane (A2) receptor antagonists. J. Med. Chem., 54:6969-6983.

Ballatore C, Brunden KR, Trojanowski JQ, Lee VM-Y, Smith AB III and Huryn D (2011) Modulation of protein-protein interactions as a therapeutic strategy for the treatment of tauopathies. Curr. Topics Med. Chem., 11:317-330.

Brunden KR, Yao Y, Potuzak JS, Ibarz Ferrer N, Ballatore C, James MJ, Hogan AL, Trojanowski JQ, Amos Smith AB, III and Lee VM-Y. (2011) The Characterization of Microtubule-Stabilizing Drugs as Possible Therapeutic Agents for Alzheimer’s Disease and Related Tauopathies. Pharmacol. Res., 63:341-351.

Ballatore C, Brunden KR, Piscitelli, F, James, MJ, Crowe A, Yao Y, Hyde E, Trojanowski JQ, Lee VM-Y and Smith AB III. (2010) Discovery of brain-penetrant, orally bioavailable aminothienopyridazine inhibitors of tau aggregation. J. Med. Chem., 53:3739-3747.

Brunden KR, Ballatore C, Crowe A, Smith AB, III, Lee, VM-Y and Trojanowski JQ (2010) Tau-directed drug discovery for Alzheimer’s disease and related tauopathies: a focus on tau assembly inhibitors. Exp. Neurol., 223:304-310.

Brunden KR, Zhang B, Carroll J, Yao Y, Potuzak JS, Hogan A-ML, Iba M, James MJ, Xie SX, Ballatore C, Smith AB III, Lee VM-Y and Trojanowski JQ (2010) Epothilone D improves microtubule density, axonal integrity and cognition in a transgenic mouse model of tauopathy. J. Neurosci., 30:13861-13866.

Brunden KR, Trojanowski JQ and Lee, VM-Y (2009) Advancements in tau-focused drug discovery for Alzheimer’s disease and related tauopathies. Nature Reviews Drug Discovery, 8:783-793.